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Abstract 
Endothelial dysfunction underlies the pathogenesis of some type 2 diabetes mellitus 
cardiovascular complications, which are the major cause of morbidity and mortality in diabetic 
patients. Knowing that glucagon-like peptide-1 (GLP-1), a brain-gut insulinotropic peptide, 
plays an important role in the dynamic of these disorder, pharmacologic GLP-1 receptor 
agonists were developed, such as liraglutide and exenatide, for its management. The present 
study was undertaken to investigate the effects of these two anti-diabetic drugs on angiogenic 
processes, using human microvascular endothelial cells (HMECs) cultures in low (5.5mM) and 
high (20mM) glucose concentrations, mimicking a normal or hyperglycemic environment, 
respectively. No cell cytotoxicity (MTS assay) of these drugs was found upon incubation of 
HMECs cultures at both glucose concentrations. Cellular proliferation (BrdU assay) was 
increased by GLP-1 receptor agonists, reaching statistical significance for exenatide. Despite 
migration (wound healing assay) and apoptosis (TUNEL assay) were not statistical significant, 
differences were found between glucose concentrations. In addition, no difference was 
observed in GLP-1 receptor expression. For better understanding of this finding, further 
studies of the underlying downstream pathways must be carried out. In conclusion, the 
present study indicates that exenatide and liraglutide may exert important physiological roles 
in endothelial cells particularly in hyperglycemic concentrations. 
 
Key words: Type 2 diabetes mellitus (T2DM); glucagon-like peptide receptor (GLP-1R); vascular 
endothelial cells; angiogenesis. 
  
Introduction 
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease characterized in the established 
state by a chronic hyperglycemic state accompanied by insufficient insulin production and 
resistance to insulin action in body tissues (Drucker et al., 2010). Nowadays, T2DM has become 
increasingly important when considered its exponentially increased prevalence and its 
associated mortality and morbidity (Cho, 2013). Due to these facts, T2DM deserves the 
intensive investigation that has been done. 
Diabetes is responsible for inducing neovascular mechanisms and impairing vascular 
regulation, resulting in several micro and macrovascular complications (Erdogdu et al., 2013; 
Goyal et al., 2010). Therefore, cardiovascular disease is the major cause of morbidity and 
mortality in diabetic patients (Kang et al., 2013; Gaspari et al., 2013). 
Glucagon-like peptide-1 (GLP-1) is a brain-gut insulinotropic peptide, produced by L cells of the 
large intestine that plays an important role in the dynamic of metabolic disease, and regulation 
of homeostasis by influencing obesity (Pi-Sunyer et al., 2015), inducing glucose-dependent 
insulin secretion, while suppressing glucagon secretion (Aaboe et al., 2008; Kim and Egan, 
2008). In addition, GLP-1 inhibits gastric motility, contributing to satiety (Krasner et al., 2014; 
Hirata et al., 2013). Thus, the GLP-1 actions have been an interesting field of study and a 
promising target for therapeutic purposes of diabetes. 
It is known that endothelial cells express glucagon-like peptide receptor (GLP-1R) and evidence 
supports GLP-1 as an important player in endothelial function (Aronis et al., 2013; Ding and 
Zhang, 2012; Xie et al., 2011). Moreover, it was recently reported that endothelial dysfunction 
is ameliorated by acute administration of GLP-1 in type 2 diabetic patients with coronary heart 
disease (Nystrom et al., 2004). Regardless of these actions, GLP-1 cannot be used as a medical 
therapy agent due to its short half-life (Hu et al., 2013). Two minutes after its secretion, GLP-1 
is rapidly degraded by dipeptidyl peptidase-4 (DPP4) to generate one metabolite that is 
truncated in the NH2-terminal incapable of connecting with GLP-1R (Aaboe et al., 2008; Hirata 
et al., 2013; Erdogdu et al., 2010). 
Therefore, several pharmacologic GLP-1R agonists were developed with the goal of preserving 
the important metabolic functions of the GLP-1 hormone (Aaboe et al., 2008), but at the same 
time with a longer half-life. 
Liraglutide and exenatide are two novel anti-diabetic drugs included on incretin-based 
therapies, used in T2DM management (Meier and Nauck, 2015). These drugs act as agonists of 
the GLP-1R and are resistant to DPP4-mediated degradation, granting a longer half-life when 
compared to GLP-1 (Aaboe et al., 2008). Interestingly, they exert their actions in a glucose-
dependent manner without the need for frequent dose adjustment (Kim and Egan, 2008; 
Meier and Nauck, 2015). 
Despite the known intervention of GLP-1 in endothelial cells, it is not established whether the 
GLP-1R agonists are capable of positively influencing endothelial dysfunction, which 
accompanies the progression of T2DM and contributes to the enormous morbidity rates found 
in these patients. 
The present study was undertaken to investigate the effects of these two anti-diabetic drugs 
on angiogenic processes, namely endothelial cell survival, proliferation, migration and 
apoptosis, using cultures of human microvascular endothelial cells in low and high glucose 
concentrations, mimicking a normal or hyperglycemic environment, respectively. 
 
Materials and Methods 
Cell culture experiments 
Human microvascular endothelial cells (HMECs) (ATCC, Spain) were used between passage 5 
and 10. HMECs were cultured in RPMI 1640 medium (Invitrogen Life Technologies, UK) 
supplemented with 10% fetal bovine serum (FBS) (Invitrogen Life Technologies, UK), 1% 
penicillin/streptomycin (Invitrogen Life Technologies, UK), 1.176 g/L of sodium bicarbonate, 
4.76 g/L of HEPES, 1 ml/L of hydrocortisone >98% (Sigma-Aldrich, Portugal), and maintained at 
37° in a humidified 5% CO2 atmosphere. Treatments were performed for 24 h in serum-free 
culture medium with two different concentrations of glucose (Glc): 5 mM and 20 mM, and 
added to cell cultures at final concentrations of 1 µM and 0.1 µM for both pharmaceutical 
agents. Controls were performed using identical volume of excipients. 
MTS toxicity assay 
HMECs were seeded (1 × 105 cells/ml) in 96-well plate, allowed to grow until 70%-90% 
confluence and then incubated with different concentrations of liraglutide and exanetide in 5 
mM or 20 mM glucose free-serum medium for 24 h. After the incubation period, cells viability 
was assessed using Cell Titer 96 Aqueous ONE Solution Reagent MTS [3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxiphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] colorimetric assay 
(Promega, USA), according to the instructions provided by the manufacturer. Optical density 
was measured at 492 nm. 
BrdU proliferation assay 
HMECs (1 × 105 cells/ml) were cultured following standard conditions or the treatment 
procedures for 24 h. Cells were also incubated with 5’-bromodeoxyuridine (BrdU) solution at a 
final concentration 0.01 mM for 2 h. Detection was then performed at 450 nm and 690 nm 
using BrdU In-Situ Detection Kit (BD Biosciences Pharmingen, USA), according to the 
manufacturer’s instructions. 
Wound healing assay 
HMECs were incubated at 37°C and were allowed to grow until 90% of confluence in a 24-well 
plate. Then, it was made a scratch with a 200 μl pipet tip and the cells were incubated for 24 h 
following the standard treatments. After incubation, cells were washed with PBS and cell 
migration to the damaged area was visualized and photographed under an inverted 
microscope at 4x objective (Nikon, UK).  
Migration capacity of the HMEC cells was then evaluated by quantifying the distance between 
the two limits of the injured area with Image J and comparing those with controls cells 
migration that was considered 100%.  
TUNEL assay 
HMECs (6 × 104 cells/ml) were grown on glass coverslips and incubated with the different 
treatments and media for 24 h. TUNEL assay (terminal deoxynucleotidyl transferase-mediated 
deoxyuridine triphosphate nick-end labeling) was performed using the In Situ Cell Death 
Detection Kit (Roche Diagnostics, Switzerland), according to the manufacturer’s instruction. 
The percentage of TUNEL-stained nuclei was evaluated in relation to every DAPI-stained nuclei 
observed, at a 10x objective. 
Western blotting assay 
Proteins were isolated from HMEC lysates using RIPA (Chemicon International, USA). Protein 
concentrations were determined using BCA kit (Thermo Fisher Scientific, USA), and 30 μg of 
protein were subjected to 8% SDS-PAGE with a 5% stacking gel. After electrophoresis, proteins 
were blotted into a Hybond nitrocellulose membrane (Amersham, USA). Immunodetection for 
GLP-R1 (1:200; Santa Cruz Biotechnology, USA) and β-actin (1:3000; Abcam, UK) was 
accomplished with enhanced chemiluminescence (ECL kit, Bio-Rad, USA). The relative intensity 
of each protein blotting analysis was measured using a computerized software program (Bio-
Rad, USA), and the expression of GLP-1R was normalized with β-actin bands, to compare the 
expression of proteins in different treatment groups. 
Statistical analysis 
All experiments were performed in duplicate or triplicate. The results are expressed as 
standard deviation (SD) ± S.E.M. Differences between the groups were evaluated for statistical 
significance using the one-way ANOVA method in GraphPad Prism program, and was 
considered significant whenever the P value was <0.05. 
 
Results 
GLP-1R agonists did not affect cell viability either in euglycemic or in hyperglycemic 
concentrations 
In order to examine whether liraglutide or exenatide have cytotoxic effects, cell viability was 
evaluated in 70-90% confluence HMECs cultures after incubation with the GLP-1R agonists by 
MTS assay. As illustrated in Figure 1, incubation with 0.01-1 µM of each agent did not 
significantly affect the number of viable cells relative to excipient-treated cell cultures 
(controls) in any of the glucose concentrations tested, indicating that no cytotoxicity was found 
in HMECs after incubation with the five different concentrations of GLP-1R agonists examined. 
Nevertheless, cell viability was slightly reduced upon incubation with increasing concentrations 
of liraglutide, particularly in hyperglycemic concentrations. Given these preliminary findings, 
the next experiments were performed using 0.1 µM, the less cytotoxic concentration, and 
whenever possible 1 µM of each agent, in the two different glycemic concentrations. 
 
Cellular proliferation was significantly augmented by both GLP-1R agonists 
The effect of liraglutide and exenatide in endothelial cells proliferation was then assessed 
using BrdU incorporation assay. Treatment with both GLP-1R agonists led to a significant 
increase in cell growth in normal (Glc 5.5 mM) and in hyperglycemic (Glc 20 mM) 
concentrations, being the results more prominent at 0.1 µM concentration of both agents. 
Nevertheless, significant differences were only seen between controls in both glycemic 
environments with the 0.1 µM concentration of exenatide in the respective glucose doses, and 
also with 1 µM concentration of this compound in normoglycemic conditions, as observed in 
Figure 2. 
 
Apoptosis and migration was not significantly induced by incretin receptor agonists 
For the study of apoptosis in HMECs treated with GLP-1R agonists, TUNEL assay was 
performed. Interestingly, in normoglycemic concentrations (Glc 5.5 mM) the number of 
apoptotic cells doubled the one from control for both incretin receptor agonists, although not 
reaching statistical significance (Figure 3A). In contrast, in hyperglycemia, apoptosis was similar 
for both agents studied. However, significant differences were only detected between the 
glucose concentrations (5.5 mM vs 20 mM) in liraglutide 0.1 µM (Figure 3A). 
Angiogenesis also requires endothelial cells to migrate. Therefore, we next examined whether 
GLP-1  receptor agonists influenced the capacity of HMECs to migrate using a wound healing 
assay. Although a tendency towards an increase in migration in hyperglycemic cultures was 
noted, those differences did not reach statistical significance (Figure 4A). No difference was 
observed among the distinct concentrations of each compound. 
 
Incretin  receptor agonists affected GLP1-R expression in HMEC by Western blotting 
To further investigate whether GLP-1R agonists played a role in GLP-1 signaling, the expression 
of GLP-1R was examined on HMEC lysates treated with 0.1 µM and 1 µM of either liraglutide 
or exenatide, in both glycemic concentrations. As it can be seen in Figure 5, no statistical 
differences were obtained regarding the expression of GLP-1R when subjected to different 
agents and glycemic conditions.
Discussion 
Liraglutide and exenatide are two GLP-1R agonists used in medical practice for the treatment 
of T2DM. They are especially interesting because they have a glucose dependent action and 
many other additional beneficial functions for the patient. Knowing that endothelial cells 
express the GLP-1R as it was demonstrated by Nystrom et al (2004), the present paper aimed 
to study the effects of these agents in the endothelial cell behavior in two different 
environments, high and low glucose concentration. 
Herein, incubation of liraglutide and exenatide in confluent HMEC cultures did not result in 
significant decreased cell viability when compared with controls. These preliminary findings 
point to the lack of cytotoxicity of these agents within the concentrations used, and prompted 
to further investigate the effect of these two agents in endothelial proliferation, death and 
migration. 
Interestingly, HMEC proliferation was increased by 0.1 M and 1 M liraglutide and exenatide, 
particularly in normoglycemic concentrations. Nevertheless, only exenatide at 0.1 M showed 
a statistical significant increase in endothelial cells proliferation in both glycemic 
environments. Erdogdu et al (2010) and Xie et al (2011), both claimed that GLP-1 enhances 
endothelial cell function, namely by promoting vascular endothelial cell proliferation. Using an 
in vitro model, our findings further indicate that GLP-1R agonists likely promote cell growth, 
and consequently survival, in a glucose independent manner.  
Inversely, cell migration and apoptosis were not affected by the incubation with the two GLP-
1R agonists. The percentage of apoptotic cells was not changed by treatment with any of the 
GLP-1R agonists. However, a tendency to an increased number of apoptotic cells observed in 
normoglycemic environment was attenuated in high glucose conditions. A vascular protective 
role of GLP-1 has already been reported by Zhan et al (2012). These findings regarding 
apoptosis, together with the lack of migration enhancement, are consistent with the ones 
reported for the GLP-1 endogenous hormone. 
We also examined whether the presence of GLP-1R agonists affected GLP-1R expression. 
Unexpectedly, no difference was observed when HMEC were incubated with the agents in 
comparison to controls. These findings led to the assumption that GLP-1 signaling could occur 
in a GLP-1R independent manner. However, the lack of GLP-1R overexpression is insufficient to 
deny any role of this receptor in GLP-1R agonists signaling, given that GLP-1R activity can be 
enhanced without changing the receptor expression. For disclosing this hypothesis further 
studies of the underlying downstream pathways must be carried out. 
Altogether, our findings showed that the GLP-1R agonists studied exhibit different effects in 
low and high glucose concentrations, implying a protective role against endothelial 
dysfunction. 
Nonetheless, further studies are needed to clarify these effects, namely using in vivo models of 
diabetes, where endothelial cells are stabilized by the vessel structure comprising a basement 
membrane, pericytes or smooth muscle and fibroblasts, which exert paracrine effects on 
endothelium. Moreover, a crosstalk between cells and the extracellular matrix components, 
play a further role in the vascular environment, which might as well influence the effect of 
GLP-1R agonists in vessel structures. 
In conclusion, our findings indicate that GLP-1  receptor agonists represent a promising field 
for the treatment of T2DM not only due to the numerous health benefits already established, 
such as the glucose-dependent action in glycemic levels, but also because of this endothelial 
protective role. Furthermore, GLP-1R agonists may ameliorate the complications arising from 
diabetes, which have a major impact on morbidity and mortality in diabetic patients. 
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600 dpi for combination halftones (photographs that also contain line art such as labeling or 
thin lines)  
Vector-based figures (e.g. figures created in Adobe Illustrator) should be submitted in EPS 
format. 
COLOR FIGURES 
In addition to the above resolution guidelines, color figures must be submitted in a CMYK 
colorspace. Do not submit color figures as RGB.  
GUIDELINES FOR COVER SUGGESTIONS 
If you would like to send suggestions for artwork related to your manuscript to be 
considered to appear on the cover of the journal, please follow these general guidelines. 
UNACCEPTABLE FIGURE FORMATS 
Do not submit figures in any of the following formats: JPG, GIF, PSD, CRD, PCT, PPT, PDF, 
XLS, DOC, DOCX, BMP, 123 (or other Lotus formats).  
VIDEOS 
Files should not be uploaded to the submission site, they should be sent by DropBox or File 
Transfer to production in the event that the article is eventually accepted. 
TO SUBMIT YOUR MANUSCRIPT ONLINE: 
- Please submit your manuscript online at http://mc.manuscriptcentral.com/jcb-wiley .  
- Click on "Check for Existing Account" . If you do not already have an account, click on 
"Create an Account". Be sure to enter Keywords.  
- Follow instructions carefully. Please review that your submission has uploaded correctly 
before clicking on the "Submit" button.  
- On completion of a successful submission, a confirmation screen with manuscript will 
appear and you will receive an e-mail confirming that the manuscript has been received by 
the Journal. If this does not happen, please check your submission. Contact 
jcb@med.uvm.edu for the editorial office or ts.mcsupport@thomson.com for ScholarOne 
Support if you require assistance  
Wiley-Japan can provide authors in Japan with a list of recommended services to check and 
improve the English of their papers before submission. Please visit 
http://www.wiley.co.jp/journals/editcontribute.html for more information.  
Routine decisions will be provided in 4-6 weeks. 
The authors must provide a primary email address that is associated with their given 
institution, or an active account that is monitored on a daily basis.  
It is suggested that original unprocessed images should be submitted as supplementary files 
alongside images that have been processed.  
Write in clear, concise English. The author is responsible for all aspects of manuscript 
preparation. Extensive changes to the manuscript will not be undertaken by the Editor or 
during the production process. 
 
Non-English Speaking Authors. Authors in non-English speaking countries are requested to 
find persons who are fully conversant and competent in English writing and also familiar 
with medical terminology to edit manuscripts before they are submitted to the editor. 
 
Wiley English Language Editing Services are available. The English Language Editing Service 
can help to ensure your paper is clearly written in standard, scientific English language 
appropriate to your discipline. 
 
Visit the following site to learn about the options: 
http://wileyeditingservices.com/en/ 
 
Using the Wiley English Language Editing Service does not guarantee that your paper will be 
accepted for publication.  
How to handle authorship disputes: a guide for new researchers By Tim Albert and 
Liz Wager 
This document aims to help new researchers prevent and resolve authorship problems. 
In particular it provides:  
 suggestions for good authorship practice that should reduce the incidence of such 
dilemmas,  
 advice on what to do when authorship problems do arise, and  
 a glossary of key concepts in authorship, with some reading lists and websites for 
those who wish to take this further.  
ARTICLE CATEGORIES: 
Articles are full-length papers presenting complete descriptions of original research, which 
have not been published and are not being considered for publication elsewhere.  
Fast Track articles are papers that present original timely research of exceptional 
significance and should make an important contribution to the field. Fast Track manuscripts 
must be concise: limited to 12 double spaced typed manuscript pages, a maximum of 35 
references, and 4 items for the presentation of data (e.g., figures, tables, micrographs). 
Authors who wish to have their manuscript considered for publication in Fast Track should 
include a brief indication of reasons why the manuscript is suitable for "fast tracking" in 
their cover letter. The names, addresses (including e-mail), telephone, and fax numbers of 
five potential reviewers must also be provided. Fast Track manuscripts should be submitted 
to one of the Executive Editors.  
Prospects are topical overviews on emerging areas of research. They summarize key 
problems, concepts, experimental approaches, and research opportunities that characterize 
a subject area. Prospects should not include previously unpublished research results. The 
Editors generally invite them; authors who wish to submit a Prospect should first consult 
with the Editors.  
(1) What is the word limit for a Prospect? 5,000-7,000 
(2) Does the word limit include references? No 
(3) Is there a limit on figures and tables? 8 
(4) Is there a reference limit? 50, maximum of 25 table and figure footnotes  
(5) What is the word limit for the abstract? 250-300 
Viewpoints include news items, meeting summaries and announcements, book reviews and 
letters to the Editor. Submitted Viewpoints are rapidly reviewed and appear in the next 
issue of the Journal. 
Benchmarks section of Journal of Cellular Biochemistry presents novel techniques and 
strategies. Each article concisely evaluates opportunities, strengths and limitations of 
experimental approaches that can expand insight into biology and pathology. Specific 
protocols are encouraged for inclusion as supplementary material. “Benchmark” articles will 
be available on PubMed.  
The objective is to provide access to novel experimental strategies. “Benchmark” articles 
should be developed to enhance awareness of capabilities to resolve complexities of cell 
structure and function. Submission of articles that focus on development of technologies 
and instrumentation to enable exploration of regulatory mechanisms previously 
unapproachable are encouraged. Coverage of topics can include (but not limited) to:  
-Cell-based and animal models for in vitro and in vivo validation of molecular components 
to regulatory networks that mediate cell cycle control, proliferation, phenotype, cell fate 
and responsiveness to physiological cues.  
-Breakthroughs in imaging and experimental approaches to discriminate subtleties in 
common or total control contributing to resolve and complexities in biological processes 
that include development, lineage commitment, tissue remodeling, apoptosis, 
pluripotency transformation and tumorigenesis.  
-Capabilities to acquire, configure and integrate data from a rapidly evolving high 
throughput genomic and proteomic screens.  
-Bioinformatic strategies that support dimensions for biological control that link to the 
prevention, early detection and treatment of human disease.  
Abstract: In 150 words describe capability of the method to provide novel insights into 
biological/biomedical control. Indicate applications for resolving fundamental regulatory 
mechanisms and/or clinically relevant questions. Present validations for the approach and 
summarize strengths as well as potential limitations.  
Presentation: Begin each “Benchmark” with an introduction that provides the background 
for the method. Focus on the unique capabilities of the approach to address compelling 
biological/biomedical questions. Highlight opportunities to increase resolution and/or scope 
of structural as well as regulatory parameters that can be evaluated.  
The method should then be presented with schematic illustrations and described with 
emphasis on instrumentation, resolution, experimental applications and complexities with 
alternative strategies. Validation should be presented and examples of data that can be 
anticipated are encouraged. Considerations of options to accommodate specialized 
requirements is informative.  
“Benchmarks” should not exceed 2500–3500 words. To maximize the utility of 
“Benchmarks” it is important for descriptions of technology to be accessible to a broad 
audience.  
Experimental protocols and specifications for instrumentation and reagents are valuable; 
but, in general, will be presented as supplemental material that is available online. 
“Benchmarks” articles will be invited by the Journal of Cellular Biochemistry editors to cover 
emerging methods and strategies. However, authors are encouraged to submit unsolicited 
manuscripts or letters of inquiry to the editorial office.  
SECTIONS: Original Research Articles should be organized in the sequence: Abstract, 
Introduction (without heading), Materials & Methods, Results, Discussion, 
Acknowledgments, References, Tables, Legends, and Figures. Use subheadings and 
paragraph titles whenever possible. Define unusual abbreviations at first mention. Units of 
measure must be written in metric units.  
TITLE PAGE must contain: 
- Complete article title 16 words or less 
- Names & affiliations (institutions) of all authors, with the corresponding author indicated 
by an asterisk. 
- Institution(s) at which the work was performed with city & state. Affiliations must be listed 
at the departmental level. Each distinct affiliation should be listed as a separate entity, with 
a superscript number that links it to the individual author(s). 
- Complete name, address, telephone number, fax number & e-mail address of 
corresponding author. 
- A running head of not more than 45 characters, including spaces. 
- Bullet point keywords (in bold). 
- Total number of text figures & tables. 
- All grant information should be provided in the following format: Contract grant 
sponsor:___; Contract grant number:___.  
ABSTRACT: This should summarize the major findings and conclusions in the paper in not 
more than 250 words compressed into a single paragraph. The abstract should be intelligible 
without reference to the rest of the paper. 
MATERIALS AND METHODS:  
For all studies involving the use of animals, the following conditions should be met: 
a. All research animals must have been obtained and used in compliance with federal, state, 
and local laws and institutional regulations. 
b. The Journal recommends that animals be maintained in accordance with the guidelines of 
the NIH (Guide for the Care and Use of Laboratory Animals, 1996), the European 
Communities Council, or equivalent regulatory guidelines in other countries. Any veterinary 
accreditation should be noted in the manuscript. 
c. The author must have received permission from their institutional Animal Care and Use 
Committee, and the manuscript must indicate that such approval was received."  
LITERATURE CITED: 
Wiley’s Journal Styles Are In EndNote 
EndNote is a software product that we recommend to our journal authors to help simplify 
and streamline the research process. Using EndNote’s bibliographic management tools, you 
can search bibliographic databases, build and organize your reference collection, and then 
instantly output your bibliography in any Wiley journal style.  
Download Reference Style for this Journal: If you already use EndNote, you can download 
the reference style for this journal online. http://endnote.com/downloads/styles 
The citation style is Author-Year. If you are not familiar with EndNote and would like to 
download in another file format, then you may select the Harvard reference system. More 
information can be found online at Wiley Author Services.  
http://authorservices.wiley.com/reference_text.asp?site=1 
Should be limited to 50. (A maximum of 25 table and figure footnotes is allowed, if 
necessary.)  
Reference should be made only to articles that are published or in press. Unpublished 
results and personal communications should be cited parenthetically in the text. Authors 
are responsible for the accuracy of the references. References in the text to the literature 
should be made by author's name followed by year of publication: 
. . . studies by Briggs (1993) reveal . . . 
. . . studies by Briggs and Porter (1994) reveal . . . 
. . . an earlier report (Briggs, 1994) . . . 
. . . earlier reports (Briggs, 1993; Briggs and Porter, 1993, 1994) . . .  
If there are more than two authors, use the first author and et al. The final list must be 
alphabetized and include only references cited in the text. Each entry must include the 
names of all authors, complete title of the work cited, and inclusive page numbers. 
Abbreviations of journal titles should follow those used in Index Medicus.  
Examples: 
Journal Article: 
Wright CD, Mülsh A, Busse R, Newman P. 1998. Generation of nitric oxide by human 
neutrophils. Biochem Biophys Res Commun 29:813-820.  
Book Cited: 
Whistler P, Wilks S. 1989. Methods in carbohydrate chemistry. New York:Academic Press. 
p.244  
Book Chapter Cited: 
Smith A. 1990. Transport of antigens: mechanisms and biological and regulatory 
consequences. In: Ariano MA, editor. Biosynthesis of heme and chlorophylls. New 
York:Wiley-Liss. p 230-278.  
LEGENDS: Each illustration must have a legend and be numbered consecutively with arabic 
numerals. Abbreviations pertaining to the labeling of figures should be listed once, 
alphabetically, and placed before the first figure containing these abbreviations.  
TABLES: Each table must be submitted as a separate file.  
ILLUSTRATIONS: Use illustrations sparingly; they should not duplicate information already 
made clear in the text. All color figures will be reproduced in full color in the journal at no 
cost to authors. Authors are encouraged to submit color illustrations that highlight the text 
and convey essential scientific information. For best reproduction, bright, clear colors 
should be used. Dark colors against a dark background do not reproduce well; please place 
your color images on a white background wherever possible. Please contact JCB Production 
at JCBprod@wiley.com for further information. All graphics and lettering must be legible 
after reduction in size. Illustrations must be numbered in order of appearance with roman 
numerals and keyed into the text.  
Research integrity 
Misconduct 
Research misconduct is defined in the US Federal Policy on Research Misconduct:  
"Research misconduct is defined as fabrication, falsification, or plagiarism in proposing, 
performing, or reviewing research, or in reporting research results."  
· Cases of suspected misconduct are handled following established processes, for example, 
those presented in the COPE Flowcharts.  
· Cases are handled at a speed that allows appropriate care to be taken.  
· Investigations may lead to retractions, expressions of concern, or other sanctions.  
Whistle blowing 
Allegations of suspected misconduct that have specific, detailed evidence to support the 
claim are investigated, whether they are raised anonymously or by named "whistle-
blowers."  
Fabrication, falsification, and image manipulation 
Changes to images can create misleading results when research data are collected as 
images. Thus inappropriate image manipulation is one form of fabrication or falsification 
that journals can identify.  
It may, however, be legitimate and even necessary to edit images. For example, the 
selective enlargement of part of an artwork may be needed to reveal features that would 
not otherwise be visible, and editing of video data may be needed to protect the privacy of 
participants.  
The six CLIP (Clinical and Laboratory Images in Publications) principles present guidance for 
documenting and publishing clinical and laboratory images. The Office of Research Integrity 
provides forensic tools for quick examination of scientific images and samples.  
· Specific features within an image should not be enhanced, obscured, removed, moved, or 
introduced.  
· Original unprocessed images must be provided by authors should any indication of 
enhancement be identified. We suggest that original unprocessed images should be 
submitted alongside any images that have been processed.  
· Adjustments to brightness or contrast are only acceptable if they apply equally across the 
entire image and are applied equally to controls, and as long as they do not obscure, 
eliminate, or misrepresent any information present in the information originally captured.  
· Excessive manipulations, such as processing to emphasize one region in the image at the 
expense of others, are inappropriate, as is emphasizing experimental data relative to the 
control.  
· Nonlinear adjustments or deleting portions of a recording must be disclosed in a figure 
legend.  
· Constructing figures from different gels, fields, exposures, and experimental series is 
discouraged. When this is necessary the component parts of composite images should be 
indicated by dividing lines clearly demarcated in the figure, and described in the legend.  
These recommendations are based on guidance developed at the Journal of Cell Biology and 
Rossner and Yamada's discussion. Cromey discusses image manipulation in " Avoiding 
twisted pixels: ethical guidelines for the appropriate use and manipulation of scientific 
digital images ."  
Other Misconduct 
·Plagiarism 
·Duplicate and redundant publication · 
·Text recycling 
·Duplicate submission 
·Duplicate information published in translations  
 
Sanctions  
Wiley has published advice about sanctions in which we refer to the COPE guidelines. 
Journals may, for example, publish a retraction, may inform the author's institution, and 
may refuse for a time to consider future work from the authors. 
COPYRIGHT/LICENSING 
If your paper is accepted, the author identified as the formal corresponding author for the 
paper will receive an email prompting them to login into Author Services; where via the 
Wiley Author Licensing Service (WALS) they will be able to complete the license agreement 
on behalf of all authors on the paper. 
For authors signing the copyright transfer agreement: 
If the OnlineOpen option is not selected the corresponding author will be presented with 
the copyright transfer agreement (CTA) to sign. The terms and conditions of the CTA can be 
previewed in the samples associated with the Copyright FAQs below: 
CTA Terms and Conditions http://authorservices.wiley.com/bauthor/faqs_copyright.asp 
For authors choosing OnlineOpen: 
If the OnlineOpen option is selected the corresponding author will have a choice of the 
following Creative Commons License Open Access Agreements (OAA): 
Creative Commons Attribution License OAA 
Creative Commons Attribution Non-Commercial License OAA 
Creative Commons Attribution Non-Commercial -NoDerivs License OAA 
To preview the terms and conditions of these open access agreements please visit the 
Copyright FAQs hosted on Wiley Author Services 
http://authorservices.wiley.com/bauthor/faqs_copyright.asp and visit 
http://www.wileyopenaccess.com/details/content/12f25db4c87/Copyright--License.html 
If you select the OnlineOpen option and your research is funded by The Wellcome Trust and 
members of the Research Councils UK (RCUK) you will be given the opportunity to publish 
your article under a CC-BY license supporting you in complying with Wellcome Trust and 
Research Councils UK requirements. For more information on this policy and the Journal’s 
compliant self-archiving policy please visit: http://www.wiley.com/go/funderstatement.  
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Wiley-Blackwell requires that all authors disclose any potential sources of conflict of 
interest. Any interest or relationship, financial or otherwise, that might be perceived as 
influencing an author’s objectivity is considered a potential source of conflict of interest. 
These must be disclosed when directly relevant or indirectly related to the work that the 
authors describe in their manuscript. Potential sources of conflict of interest include but are 
not limited to patent or stock ownership, membership of a company board of directors, 
membership of an advisory board or committee for a company, and consultancy for or 
receipt of speaker’s fees from a company. The existence of a conflict of interest does not 
preclude publication in this journal.  
If the authors have no conflict of interest to declare, they must also state this at submission. 
It is the responsibility of the corresponding author to review this policy with all authors and 
to collectively list in the cover letter to the Editor-in-Chief, in the manuscript (under the 
Acknowledgments section), and in the online submission system ALL pertinent commercial 
and other relationships.  
Supplementary Online Material: Authors may submit supplementary material for their 
articles to be posted in the electronic version of the journal. There are no restrictions on file 
types, however please keep in mind that the more universal the file type the more 
accessible it will be to the community. All supplementary material must be submitted online 
as "Supplementary Material" for peer review.  
Reprints: Reprints may be purchased at 
https://caesar.sheridan.com/reprints/redir.php?pub=10089&acro=jcb. 
 
Note to NIH Grantees. Pursuant to NIH mandate, Wiley-Blackwell will post the accepted 
version of contributions authored by NIH grant-holders to PubMed Central upon 
acceptance. This accepted version will be made publicly available 12 months after 
publication. For further information, see www.wiley.com/go/nihmandate. 
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